284 related items for PubMed ID: 9205762
21. Endoscopic double-blind controlled trial of ranitidine vs placebo in the short-term treatment of duodenal ulcer.
Dobrilla G, de Pretis G, Felder M, Chilovi F.
Hepatogastroenterology; 1981 Feb; 28(1):49-52. PubMed ID: 6111528
[Abstract] [Full Text] [Related]
22. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
Albet C, Pérez JA, Rozman E, Márquez M, Herrero E, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
[Abstract] [Full Text] [Related]
23. Roxatidine versus ranitidine in the treatment of duodenal ulcer: a randomized, double blind, controlled, multicenter study in Thailand.
Kachintorn U, Chinapak O, Vongphanich V, Kositchaiwat C, Lekhayananda S, Khow-ean U, Suttinont C, Saowaros V, Kludchareon N, Leethochawalit M.
J Med Assoc Thai; 1995 Dec; 78(12):641-7. PubMed ID: 8868007
[Abstract] [Full Text] [Related]
24. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Romero A, Villamayor F, Palop D, Falcó J, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
[Abstract] [Full Text] [Related]
25. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial.
Kuipers EJ, Hazenberg HJ, Quik RF, Hazenberg BP, de Zwart PA.
Neth J Med; 1990 Aug; 37(1-2):58-62. PubMed ID: 1977089
[Abstract] [Full Text] [Related]
26. [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy].
Baglioni A, Barbara L, Bianchi-Porro G, Blasi A, Canelli B, Cheli R, Dal Monte R, Dammann HG, Francavilla A, Hentschel E.
Z Gastroenterol; 1985 Dec; 23(12):665-9. PubMed ID: 2868581
[Abstract] [Full Text] [Related]
27. Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Nizatidine Multicenter Duodenal Ulcer Study Group.
Cherner JA, Cloud ML, Offen WW, Latz JE.
Am J Gastroenterol; 1989 Jul; 84(7):769-74. PubMed ID: 2568086
[Abstract] [Full Text] [Related]
28. Roxatidine acetate as maintenance treatment for patients with peptic ulcer disease. The European Cooperative Roxatidine Study Group.
Clin Ther; 1991 Jul; 13(1):47-57. PubMed ID: 1674231
[Abstract] [Full Text] [Related]
29. Chronic toxicity of ebrotidine in rats and dogs.
Romero A, Grau MT, Villamayor F, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):498-504. PubMed ID: 9205752
[Abstract] [Full Text] [Related]
30. New H2-receptor antagonist--roxatidine acetate--in treatment of duodenal ulcer.
Amarapurkar DN, Parikh SS, Desai HG.
J Assoc Physicians India; 1993 Aug; 41(8):496-7. PubMed ID: 7904993
[Abstract] [Full Text] [Related]
31. [Dose finding study of telenzepine (1.5 vs. 3 vs 5 mg once daily) in acute treatment of duodenal ulcer. A double-blind, randomized, multicenter parallel group comparison].
Hüttemann W, Schneider A.
Med Klin (Munich); 1989 Dec 15; 84(12):574-7. PubMed ID: 2695806
[Abstract] [Full Text] [Related]
32. [Intermittent treatment or preventive treatment of recurrence in duodenal ulcer disease? A controlled, double-blind study with 150 mg ranitidine daily for one year].
Mignon M, Ruszniewski P, Pappo M, Alberola B, Georges D.
Gastroenterol Clin Biol; 1990 Dec 15; 14(10):732-8. PubMed ID: 2262119
[Abstract] [Full Text] [Related]
33. The treatment of duodenal and gastric ulcer with ranitidine--a controlled, multicentre clinical trial.
Gibinski K, Nowak A, Gabryelewicz A, Szalaj W, Hasik J, Klincewicz H, Pokora J, Radwan P, Kosecki P, Pachlewski J.
Dtsch Z Verdau Stoffwechselkr; 1982 Dec 15; 42(2-3):64-9. PubMed ID: 6286274
[Abstract] [Full Text] [Related]
34. Role of histamine-2 receptor antagonists after simple closure of perforated duodenal ulcer--a double blind randomised, controlled study.
Sevvel S, Ananthakrishnan N, Kate V.
Trop Gastroenterol; 1996 Dec 15; 17(4):227-9. PubMed ID: 9094865
[Abstract] [Full Text] [Related]
35. Subacute toxicity of ebrotidine in rats and dogs.
Romero A, Grau MT, Villamayor F, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr 15; 47(4A):492-7. PubMed ID: 9205751
[Abstract] [Full Text] [Related]
36. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC, Fiske K, Lyne A.
Clin Ther; 2007 Sep 15; 29(9):1967-79. PubMed ID: 18035196
[Abstract] [Full Text] [Related]
37. [Single evening administration of a new antimuscarinic agent telenzepine in therapy of acute duodenal ulcer. Results of a randomized double-blind comparative study versus pirenzepine].
Dammann HG, Dreyer M, Wolf N, Müller P, Merk-Härtelt B, Simon B.
Z Gastroenterol; 1989 Apr 15; 27(4):203-6. PubMed ID: 2658396
[Abstract] [Full Text] [Related]
38. Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
Romero A, Gómez F, Villamayor F, Ballesta A, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr 15; 47(4A):524-7. PubMed ID: 9205757
[Abstract] [Full Text] [Related]
39. Carcinogenicity studies on ebrotidine.
Romero A, Rives A, Grau MT, Villamayor F, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr 15; 47(4A):515-9. PubMed ID: 9205755
[Abstract] [Full Text] [Related]
40. Gastroprotective and antisecretory effects of ebrotidine.
Konturek SJ, Maczka J, Kaminski K, Sito E, Torres J, Oleksy J.
Scand J Gastroenterol; 1992 Jun 15; 27(6):438-42. PubMed ID: 1352908
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
